Coventry, UK, 8th May 2017 / Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has appointed Laboratoires Plasto Santé to manufacture its first drug delivery patches.
The first batch of patches, based on Medherant’s proprietary TEPI Patch® technology, will be used for clinical studies of the company’s revolutionary ibuprofen patches. The new studies, designed to test safety and efficacy, are planned to start in the autumn of 2017.
Nigel Davis, CEO of Medherant, said, “We’re delighted to have Laboratoires Plasto Santé as our contract manufacturer at this exciting time in our company’s growth. Combining our TEPI Patch® technology with Laboratoires Plasto Santé’s product manufacturing expertise will enable us to start clinical trials and facilitate rapid growth of our library of patch-delivered drugs.”
Bruno Loiseau, Managing Director of Laboratoires Plasto Santé, said “We’re looking forward to working with Medherant as it progresses its patches towards the market. We are expanding our patch production capacity and will support Medherant with our expertise in transdermal delivery systems as they bring TEPI Patch® ibuprofen to market and begin clinical studies with other products.”
For further information, contact:
T: +44 (0)24 7632 3060
Laboratoires Plasto Santé
Business Development Director
T: +33 (0)684 21 75 18
Media Relations, Sciad Communications
T: +44 (0)20 7470 8801
Notes for Editors
About Medherant Ltd
Medherant is a developer of next generation transdermal drug delivery patches founded by Professor David Haddleton and the University of Warwick. Since March 2015, Medherant has been using its world-leading expertise in bioadhesives and polymer chemistry to create new adhesive transdermal patches to expand and advance the library of drugs that can be delivered using patches. The TEPI Patch® technology, developed by Medherant, improves upon existing patches by significantly increasing drug loading capability, efficacy and patient user experience.
Medherant is commercialising novel transdermal patch-based products and solutions that are capable of delivering a much wider range of drugs than traditional patch products, while offering levels of dose control that other topical delivery methods do not have. Medherant’s first products are currently in pre-clinical testing and entering clinical testing later in 2017.
The Company is currently seeking partnerships with pharmaceutical companies wishing to extend the commercial life of drug patents, or with products for which development has halted due to the compound being unsuitable for oral delivery.
About Laboratoires Plasto Santé SAS
Laboratoires Plasto Santé is an independent drug delivery company specialising in Transdermal & Topical patches as well as Oral Thin Films technologies. Based in France with a GMP facility for Europe and the US market, Laboratoires Plasto Santé is about to complete an investment that will double the size of its clean rooms and provide larger capacities for partnerships.
Laboratoires Plasto Santé offers a full range of services: formulation, proof of concept studies, manufacturing from pilot to large industrial scale production, and analytical studies for drug market approval.
In recognition of its continuous growth, the company is proud to be ranked 601 in the 2017 Financial Times list of the 1000 Europe’s fastest growing companies.